Neurogene Says NGN-401 Gene Therapy For Rett Syndrome Has Been Selected To Participate In FDA Support For Clinical Trials Advancing Rare Disease Therapeutics Pilot Program

Benzinga · 06/03 11:45

As part of the START Program, Neurogene will have opportunities for enhanced communications with the FDA, with the aim to further accelerate the pace of NGN-401's development. Two dose levels of NGN-401 are being evaluated in a Phase 1/2 clinical trial.